TFF Pharmaceuticals IncNASDAQ:TFFP
- LAST PRICE1.8750
- TODAY'S CHANGE (%)0.1055 (5.9621%)
- Bid / Lots1.7900/ 1
- Ask / Lots1.9000/ 1
- Open / Previous Close1.7900 / 1.7695
- Day Range
- 52 Week Range
- Volume9,812
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TFFP |
|---|---|---|
| 09:56 ET | 2000 | 1.7847 |
| 09:57 ET | 950 | 1.84 |
| 10:26 ET | 500 | 1.845 |
| 10:46 ET | 200 | 1.84 |
| 12:16 ET | 100 | 1.8312 |
| 03:34 ET | 909 | 1.86 |
| 03:36 ET | 150 | 1.88 |
| 03:54 ET | 1330 | 1.8999 |
| 03:56 ET | 202 | 1.91 |
| 03:57 ET | 1907 | 1.83 |
| 03:59 ET | 300 | 1.875 |
Jun 26, 2024
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities, from 7:00AM ET on Wednesday Jun 26, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TFF Pharmaceuticals Inc | 5.5M | -0.2x | --- |
Soligenix Inc | 4.4M | -0.4x | --- |
BioCardia Inc | 5.4M | -0.4x | --- |
Marizyme Inc | 4.1M | 0.0x | --- |
Notable Labs Ltd | 5.2M | -0.3x | --- |
Aditxt Inc | 2.8M | 0.0x | --- |
Company Information
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Contact Information
- Headquarters
- 2600 Via Fortuna Ste 360AUSTIN, TX, United States 78746-7983
- Phone
- ---
- Fax
- 302-655-5049
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5M |
|---|---|
Revenue (TTM) | $885.7K |
Shares Outstanding | 3.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.34 |
EPS | $-10.20 |
Book Value | $4.04 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,325.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
